Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction

Journal of Urology

Volumn 172, Issue 6 I, 2004, Pages 2347-2349

  Pavone, C ^a   Curto, F ^a   Anello, G ^a   Serretta, V ^a   Almasio, P L ^a   Pavone Macaluso, M ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apomorphine; Impotence; Penis; Sildenafil

Indexed keywords

APOMORPHINE; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HEADACHE; HETEROSEXUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PENIS ERECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL INTERCOURSE; SIDE EFFECT; SOMNOLENCE; VASODILATATION;

EID: 8644248333     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000144032.39336.28     Document Type: Article

References (9)

1. Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J. and McKinlay, J. B.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Ageing Study. J Urol, 151: 54, 1994
2. Melman, A. and Gingell, J. C.: The epidemiology and pathophysiology of erectile dysfunction. J Urol, 161: 5, 1999
3. Presented at First International Consultation on Erectile Dysfunction: Sponsored by World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societé Internationale d'Urologie (SIU), Paris, France, July 1-3, 1999
4. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M. et al: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res, 8: 47, 1996
5. Argiolas, A. and Hedlund, H.: The pharmacology and clinical pharmacokinetics of apomorphine SL. BJU Int, 88: 18, 2001
6. Rampin, O.: Mode of action of a new oral treatment for erectile dysfunction: apomorphine SL. BJU Int, suppl., 88: 22, 2001
7. Perimenis, P., Gyftopoulos, K., Giannitsas, K., Markou, S. A., Tsota, I., Chrysanthopoulou, A. et al: A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res, 16: 2, 2004
8. Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J. and Mishra, A.: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 49: 822, 1997
9. Dula, E., Bukofzer, S., Perdok, R., George, M. and Apomorphine SL Study Group: Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol, 39: 558, 2001